Detalles de la búsqueda
1.
Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.
BMC Neurol;
22(1): 35, 2022 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35073872
2.
Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population.
Mov Disord;
36(1): 133-142, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33031604
3.
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
Liver Int;
40(5): 1032-1041, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31821716
4.
The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States.
Mov Disord;
34(2): 236-245, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30589953
5.
Lifestyle-related attitudes: do they explain self-rated health and life-satisfaction?
Qual Life Res;
27(5): 1227-1235, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29302851
6.
OFF episode quality of life impact scale (OFFELIA): A new measure of quality of life for off episodes in Parkinson's disease.
Parkinsonism Relat Disord;
123: 106070, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38503261
7.
Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.
Adv Ther;
39(5): 2009-2024, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35247187
8.
Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses.
Neurol Ther;
11(2): 711-723, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35192177
9.
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
Pharmacoeconomics;
40(5): 559-574, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35307793
10.
Advanced-Stage Parkinson's Disease: From Identification to Characterization Using a Nationwide Database.
Mov Disord Clin Pract;
9(4): 458-467, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35586537
11.
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.
Neurol Ther;
11(1): 303-318, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015215
12.
Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis.
Parkinsonism Relat Disord;
86: 52-57, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33857722
13.
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
Adv Ther;
38(6): 2854-2890, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34018146
14.
Low Sustainment of High-Dose Oral Medication Regimens for Advanced Parkinson's Disease in Medicare Beneficiaries.
J Parkinsons Dis;
11(2): 675-684, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33386811
15.
Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications.
Parkinsonism Relat Disord;
92: 59-66, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34695657
16.
Use of a medication-based algorithm to identify advanced Parkinson's disease in administrative claims data: Associations with claims-based indicators of disease severity.
Clin Park Relat Disord;
3: 100046, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-34316631
17.
The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinson's Disease Population.
Forum Health Econ Policy;
23(2): 1-23, 2020 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33984886
18.
The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson's disease.
J Med Econ;
23(3): 297-307, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31779508
19.
The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
J Med Econ;
20(11): 1207-1215, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28895769
20.
Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.
Mov Disord Clin Pract;
4(6): 829-837, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29242809